Electric Countershock

• 

  Subject Areas on Research

  • 2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion). 
  • 2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion). 
  • 2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion). 
  • 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. 
  • 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. 
  • 6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias. 
  • A change of heart. 
  • A covariance-based algorithm: a novel technique for rhythm discrimination in ICDs. 
  • A four-shock Bayesian up-down estimator of the 80% effective defibrillation dose. 
  • A novel ultrasound technique to estimate right ventricular geometry during fibrillation. 
  • ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. 
  • ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. 
  • Activation during ventricular defibrillation in open-chest dogs. Evidence of complete cessation and regeneration of ventricular fibrillation after unsuccessful shocks. 
  • Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocks. 
  • Administrative Codes for Capturing In-Hospital Cardiac Arrest. 
  • Altering the topology of gap junctions a major therapeutic target for atrial fibrillation. 
  • Amplatzer vascular plug closure of a subclavian arteriovenous fistula associated with implantable cardioverter-defibrillator implantation. 
  • An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. 
  • An unusual case of ventricular fibrillation. 
  • An up-down Bayesian, defibrillation efficacy estimator. 
  • Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. 
  • Analysis of the defibrillation efficacy for 5-ms waveforms. 
  • Anesthetic management of an AAI pacemaker patient with paroxysmal atrial fibrillation during colorectal surgery. 
  • Antithrombotic therapy in atrial fibrillation. 
  • Applying the new STEMI guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction. 
  • Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. 
  • Association Between Prompt Defibrillation and Epinephrine Treatment With Long-Term Survival After In-Hospital Cardiac Arrest. 
  • Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT. 
  • Association of Bystander and First-Responder Intervention With Survival After Out-of-Hospital Cardiac Arrest in North Carolina, 2010-2013. 
  • Association of Public Health Initiatives With Outcomes for Out-of-Hospital Cardiac Arrest at Home and in Public Locations. 
  • Associations between understanding of current treatment intent, communication with healthcare providers, preferences for invasive life-sustaining interventions and decisional conflict: results from a survey of patients with advanced heart failure in Singapore. 
  • Atrial ejection force: a noninvasive assessment of atrial systolic function. 
  • Atrial fibrillation in heart failure: what should we do? 
  • Atrial fibrillation: conventional wisdom reappraised. 
  • Atrial fibrillation: rate control versus maintenance of sinus rhythm. 
  • Atrial flutter, atrial fibrillation, and other primary atrial tachycardias. 
  • Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect. 
  • Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. 
  • Body mass index and outcomes of in-hospital ventricular tachycardia and ventricular fibrillation arrest. 
  • COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. 
  • Cardiac mapping at Duke Medical Center. 
  • Cardiac potential and potential gradient fields generated by single, combined, and sequential shocks during ventricular defibrillation. 
  • Cardiac resuscitation in the operating room: reflections on how we can do better. 
  • Cardiac resynchronization therapy in heart failure patients: an update. 
  • Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. 
  • Cardiac-resynchronization therapy for the prevention of heart-failure events. 
  • Cardioversion and subsequent quality of life and natural history of atrial fibrillation. 
  • Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. 
  • Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. 
  • Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. 
  • Centers for Medicare and Medicaid Services' Decision to Reconsider Coverage Indications for ICDs: Where to Now? 
  • Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. 
  • Choosing the optimal monophasic and biphasic waveforms for ventricular defibrillation. 
  • Collaborative care for the wearable cardioverter defibrillator patient: Getting the patient and medical team "vested and active". 
  • Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. 
  • Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. 
  • Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. 
  • Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. 
  • Comparison of activation during ventricular fibrillation and following unsuccessful defibrillation shocks in open-chest dogs. 
  • Comparison of defibrillation probability of success curves for an endocardial lead configuration with and without an inactive epicardial patch. 
  • Comparison of team-focused CPR vs standard CPR in resuscitation from out-of-hospital cardiac arrest: Results from a statewide quality improvement initiative. 
  • Comparison of upper limit of vulnerability and defibrillation probability of success curves using a nonthoracotomy lead system. 
  • Constructing a multichannel electrocardiography system from a few standardized, high-level components. 
  • Construction of a very high-density extracellular electrode array. 
  • Cost-effectiveness of automated external defibrillators on airlines. 
  • Cryoablation of drug-resistant ventricular tachycardia in a patient with a variant of scleroderma. 
  • Current concepts for selecting the location, size and shape of defibrillation electrodes. 
  • Current density and electrically induced ventricular fibrillation. 
  • Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults. 
  • Defibrillation and the geometry of the heart: a novel measurement with implications for defibrillation mechanisms. 
  • Defibrillation and the upper limit of vulnerability to fibrillation in a transthoracic guinea pig model. 
  • Defibrillation causes immediate cardiac dilation in humans. 
  • Defibrillation coil reversal: a rare cause of abnormal noise and inappropriate shocks. 
  • Defibrillation time intervals and outcomes of cardiac arrest in hospital: retrospective cohort study from Get With The Guidelines-Resuscitation registry. 
  • Defibrillation with low voltage using a left ventricular catheter and four cutaneous patch electrodes in dogs. 
  • Designation and distribution of events in the Multicenter UnSustained Tachycardia Trial (MUSTT). 
  • Determination of effects of internal countershock by direct cardiac recordings during normal rhythm. 
  • Disease understanding in patients newly diagnosed with atrial fibrillation. 
  • Do ICD lead recalls affect physician--or patient--behavior? If not, why not? 
  • Early administration of epinephrine (adrenaline) in patients with cardiac arrest with initial shockable rhythm in hospital: propensity score matched analysis. 
  • Early ambulation after 5 French diagnostic cardiac catheterization: results of a multicenter trial. 
  • Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. 
  • Early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction. 
  • Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis. 
  • Effect of defibrillation threshold testing on heart failure hospitalization or death in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). 
  • Effect of microscopic and macroscopic discontinuities on the response of cardiac tissue to defibrillating (stimulating) currents. 
  • Effect of pulse separation between two sequential biphasic shocks given over different lead configurations on ventricular defibrillation efficacy. 
  • Effect of rapid pacing and T-wave scanning on the relation between the defibrillation and upper-limit-of-vulnerability dose-response curves. 
  • Effective defibrillation in pigs using interleaved and common phase sequential biphasic shocks. 
  • Effectiveness of high rate and delayed detection ICD programming by race: A MADIT-RIT substudy. 
  • Effects of electroporation on the transmembrane potential distribution in a two-dimensional bidomain model of cardiac tissue. 
  • Effects of electroporation on transmembrane potential induced by defibrillation shocks. 
  • Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy. 
  • Effects of monophasic and biphasic shocks on action potentials during ventricular fibrillation in dogs. 
  • Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. 
  • Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). 
  • Electric field stimulation of excitable tissue. 
  • Electrophysiology in China: a special supplement. Introduction. 
  • Electroporation and shock-induced transmembrane potential in a cardiac fiber during defibrillation strength shocks. 
  • Epicardial mapping of ventricular defibrillation with monophasic and biphasic shocks in dogs. 
  • Epicardial sock mapping following monophasic and biphasic shocks of equal voltage with an endocardial lead system. 
  • Estimating defibrillation efficacy using combined upper limit of vulnerability and defibrillation testing. 
  • Estimating the 95% effective defibrillation dose. 
  • European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). 
  • Evaluation of outpatients experiencing implantable cardioverter defibrillator shocks associated with minimal symptoms. 
  • Evaluation of the effect of transthoracic cardioversion from ventricular tachycardia to sinus rhythm on left atrial mechanical function. 
  • Evolution of the CCU from rhythm, function and protection to reperfusion and beyond: a personal journey and perspective. 
  • Experimental cardiac tachyarrhythmias in guinea pigs. 
  • Experimental evidence of improved transthoracic defibrillation with electroporation-enhancing pulses. 
  • Experimental verification of theoretical predictions concerning the optimum defibrillation waveform. 
  • Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AF. 
  • Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks. 
  • Field stimulation of cardiac fibers with random spatial structure. 
  • Finite element analysis of bioelectric phenomena. 
  • Follow-up of patients with new cardiovascular implantable electronic devices: are experts' recommendations implemented in routine clinical practice? 
  • Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients. 
  • HAZARDS OF ELECTRIC SHOCK IN CARDIOLOGY. 
  • High and low strength nonsynchronized shocks given during canine ventricular tachycardia. 
  • Impact of Tachyarrhythmia Detection Rate and Time from Detection to Shock on Outcomes in Nationwide US Practice. 
  • Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. 
  • Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions. 
  • Implantable cardioverter-defibrillator lead revision following left ventricular assist device implantation. 
  • Implantable intravascular defibrillator: evaluation of defibrillation waveforms with inferior vena cava electrode system. 
  • Implementation of a National 5-Year Plan for Prehospital Emergency Care in Singapore and Impact on Out-of-Hospital Cardiac Arrest Outcomes From 2011 to 2016. 
  • Importance of electrode conductive surface area and edge effects on ventricular defibrillation efficacy. 
  • Improved defibrillation thresholds with large contoured epicardial electrodes and biphasic waveforms. 
  • In-hospital management of patients with atrial flutter. 
  • Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. 
  • Inclusion of junction elements in a linear cardiac model through secondary sources: application to defibrillation. 
  • Incomplete relaxation between beats after myocardial hypoxia and ischemia. 
  • Increasing the computational efficiency of a bidomain model of defibrillation using a time-dependent activating function. 
  • Influence of epicardial patches on defibrillation threshold with nonthoracotomy lead configurations. 
  • Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial. 
  • Influence of shock strength and timing on induction of ventricular arrhythmias in dogs. 
  • Initial Interventions for Out-of-Hospital Cardiac Arrest--Reply. 
  • Internal cardioversion in two patients with atrial fibrillation refractory to external cardioversion. 
  • Interventional strategies associated with improvements in survival for out-of-hospital cardiac arrests in Singapore over 10 years. 
  • Is the second phase of a biphasic defibrillation waveform the defibrillating phase? 
  • Large sample test of defibrillation waveform sensitivity. 
  • Left ventricular geometry immediately following defibrillation: shock-induced relaxation. 
  • Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. 
  • Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. 
  • MY APPROACH to the risk stratification of patients for sudden cardiac death. 
  • Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. 
  • Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry. 
  • Mechanism of cardiac defibrillation. A different point of view. 
  • Minimum energy single-shock internal atrial defibrillation in sheep. 
  • Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. 
  • Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation: Systematic review and network meta-analysis. 
  • More bad news for cardiac resynchronization therapy in atrial fibrillation patients: what to do? 
  • Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). 
  • Multistate 5-Year Initiative to Improve Care for Out-of-Hospital Cardiac Arrest: Primary Results From the HeartRescue Project. 
  • Mystery of biphasic defibrillation waveform efficacy is it calcium? 
  • Novel ICD Programming and Inappropriate ICD Therapy in CRT-D Versus ICD Patients: A MADIT-RIT Sub-Study. 
  • One-dimensional model of cardiac defibrillation. 
  • Open-thorax guinea pig model for defibrillation. 
  • Optical measurements of transmembrane potential changes during electric field stimulation of ventricular cells. 
  • Optimal management of Riata leads with no known electrical abnormalities or externalization: a decision analysis. 
  • Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis. 
  • Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. 
  • Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. 
  • Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. 
  • Outcomes after nonemergent electrical cardioversion for atrial arrhythmias. 
  • Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. 
  • Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter. 
  • Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. 
  • PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy. 
  • Patterns of oral anticoagulation use with cardioversion in clinical practice. 
  • Periodic conductivity as a mechanism for cardiac stimulation and defibrillation. 
  • Perioperative morbidity and mortality in combined vs. staged approaches to carotid and coronary revascularization. 
  • Physicians' knowledge and attitudes regarding implantable cardioverter-defibrillators. 
  • Physicians' perceptions of shared decision-making for implantable cardioverter-defibrillators: Results of a physician survey. 
  • Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. 
  • Pre-hospital synthesized 12-lead ECG ischemia monitoring with trans-telephonic transmission in acute coronary syndromes: pilot study results of the ST SMART trial. 
  • Predicting the potential gradient field in ventricular fibrillation from shocks delivered in paced rhythm. 
  • Predictors of an inadequate defibrillation safety margin at ICD implantation: insights from the National Cardiovascular Data Registry. 
  • Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. 
  • Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. 
  • Prevention of recurrent sudden cardiac arrest: role of provocative electropharmacologic testing. 
  • Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients. 
  • Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. 
  • Prolongation of repolarization time by electric field stimulation with monophasic and biphasic shocks in open-chest dogs. 
  • Prolonged cardiopulmonary resuscitation and outcomes after out-of-hospital cardiac arrest. 
  • Pulmonary edema post-cardioversion: a potential calcium signalling problem. 
  • Random nature of fibrillation leads to the probabilistic nature of defibrillation. 
  • Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. 
  • Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. 
  • Rationale and design for the Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation (DETERMINE) trial. 
  • Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. 
  • Rationale and design of the Home Automatic External Defibrillator Trial (HAT). 
  • Reduction in Inappropriate ICD Therapy in MADIT-RIT Patients Without History of Atrial Tachyarrhythmia. 
  • Remote monitoring of cardiac implantable electronic devices (CIED). 
  • Response of relatively refractory canine myocardium to monophasic and biphasic shocks. 
  • Response to letter regarding, "PR interval identifies clinical response in patients with non-left bundle branch block: a multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy sub-study" by Kutyifa et al. 
  • Review of advanced heart failure device diagnostics examined in clinical trials and the potential benefit from monitoring capabilities. 
  • Rhythm control in atrial fibrillation. 
  • Rhythm control versus rate control for atrial fibrillation and heart failure. 
  • Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. 
  • Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. 
  • Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT. 
  • Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. 
  • Spatial potential and current distributions along transvenous defibrillation electrodes: variation of electrode characteristics. 
  • Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. 
  • Strategies for improving survival after in-hospital cardiac arrest in the United States: 2013 consensus recommendations: a consensus statement from the American Heart Association. 
  • Strength-duration and probability of success curves for defibrillation with biphasic waveforms. 
  • Sudden cardiac arrest in ESRD patients. 
  • Surface coverage effects on defibrillation impedance for transvenous electrodes. 
  • Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. 
  • Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. 
  • Survival in Women Versus Men Following Implantation of Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy Devices in a Large, Nationwide Cohort. 
  • THE NATURE AND MANAGEMENT OF ELECTRIC SHOCK. 
  • Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. 
  • The Association of Duration of participation in get with the guidelines-resuscitation with quality of Care for in-Hospital Cardiac Arrest. 
  • The Relationship Between Level of Adherence to Automatic Wireless Remote Monitoring and Survival in Pacemaker and Defibrillator Patients. 
  • The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II. 
  • The defibrillation efficacy of high frequency alternating current sinusoidal waveforms in guinea pigs. 
  • The effect of cardiac compression on defibrillation efficacy and the upper limit of vulnerability. 
  • The effect of inducing ventricular fibrillation with 50-Hz pacing versus T wave stimulation on the ability to defibrillate. 
  • The effect of intermittent atrial tachyarrhythmia on heart failure or death in cardiac resynchronization therapy with defibrillator versus implantable cardioverter-defibrillator patients: a MADIT-CRT substudy (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). 
  • The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients. 
  • The nitric oxide synthase inhibitor N(G)-nitro-L-arginine decreases defibrillation-induced free radical generation. 
  • The nitric oxide synthase inhibitor N(G)-nitro-L-arginine decreases defibrillation-induced free radical generation. 
  • The potential gradient field created by epicardial defibrillation electrodes in dogs. 
  • The probability of defibrillation success and the incidence of postshock arrhythmia as a function of shock strength. 
  • The role of bystanders, first responders, and emergency medical service providers in timely defibrillation and related outcomes after out-of-hospital cardiac arrest: Results from a statewide registry. 
  • The ventricular defibrillation and upper limit of vulnerability dose-response curves. 
  • Therapies to prevent heart failure post-myocardial infarction. 
  • Three-dimensional potential gradient fields generated by intracardiac catheter and cutaneous patch electrodes. 
  • Thromboembolism after negative TEE. 
  • Thrombolytic therapy in patients requiring cardiopulmonary resuscitation. 
  • Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. 
  • Transesophageal echocardiography before cardioversion. 
  • Transesophageal echocardiography versus oral anticoagulation before electrical cardioversion of atrial fibrillation: what about atrial clot size? 
  • Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. 
  • Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. 
  • Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis. 
  • Virtual electrode effects in transvenous defibrillation-modulation by structure and interface: evidence from bidomain simulations and optical mapping. 
  • Wearable Cardioverter Defibrillator "The Lifevest": Device Design, Limitations, and Areas of Improvement. 
  • Why are (only) some infarcted hearts arrhythmogenic? 
  • Why do some patients have high defibrillation thresholds at defibrillator implantation? Answers from basic research. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Dupre, Matthew E., Associate Professor in Population Health Sciences, Center for the Study of Aging and Human Development
  • Henriquez, Craig S., Professor of Biomedical Engineering, Biomedical Engineering
  • Middleton, John Paul, Professor of Medicine, Medicine, Nephrology